Results 101 to 110 of about 21,137 (209)
ABSTRACT A 60‐year‐old female with abdominal pain and nausea was diagnosed with gallbladder cancer (cT3aN2M1, cStage IVB). Distant metastases had disappeared after 10 courses of chemotherapy, followed by conversion surgery consisting of subtotal stomach‐preserving pancreaticoduodenectomy, partial hepatectomy, and dissection of para‐aortic and regional ...
Yuki Ito +9 more
wiley +1 more source
Regional quantification of metabolic liver function using hyperpolarized [1-13C] pyruvate MRI
Assessment of liver function is essential before partial hepatectomy to predict the risk of post hepatectomy liver failure, a severe and life-threatening complication.
Uffe Kjaergaard +13 more
doaj +1 more source
LGG was separated from L. gracile and its hepatoprotective effect was investigated. LGG significantly reduced the mortality, ROS and MDA content in alcohol‐injured liver cells. LGG up‐regulated 156 mRNAs (63 miRNAs) and down‐regulated 1529 mRNAs (35 miRNAs).
Yi‐Long Ma +9 more
wiley +1 more source
ABSTRACT Background Virtual MR elastography (VMRE) and MRE have been proposed for liver fibrosis staging in metabolic dysfunction‐associated steatotic liver disease (MASLD), but VMRE's diagnostic performance remains debated. Purpose To assess the inter‐visit and inter‐reader reproducibility of fat‐uncorrected and fat‐corrected diffusion‐weighted ...
Anton Volniansky +13 more
wiley +1 more source
Advances in Diagnosis and Treatment With Cholangiopancreatoscopy
ABSTRACT Endoscopic retrograde cholangiopancreatography (ERCP) remains the standard for diagnosing and treating pancreatobiliary diseases. Although non‐invasive imaging modalities have significantly improved, ERCP continues to play an indispensable role in clinical practice. However, ERCP has inherent limitations. Diagnostic challenges persist in cases
Takeshi Ogura +2 more
wiley +1 more source
The platelet count can be used to predict liver function at the time of evaluation of progressive disease (PD) after atezolizumab plus bevacizumab (ATZ/BEV) therapy in patients with u‐HCC. Treatment strategies in u‐HCC patients with low platelet counts should be conducted by taking into account deterioration of liver function after ATZ/BEV.
Ryo Sato +21 more
wiley +1 more source
Cell networks in the mouse liver during partial hepatectomy. [PDF]
Li B +8 more
europepmc +1 more source

